药业公司跨界收购半导体企业被认定为误导性陈述！公司及责任人拟被罚510万

Core Viewpoint - Zhejiang Sunflower Health Technology Co., Ltd. is facing administrative penalties from the Zhejiang Securities Regulatory Bureau for misleading statements regarding its asset acquisition plan, which led to significant stock price increases and trading volume [1][3]. Group 1: Administrative Penalties - The company and its responsible individuals, including Chairman Wu Shaoqin and Secretary Li Lan, are accused of failing to ensure accurate and complete information disclosure, resulting in misleading statements about the acquisition of 100% of Zhangzhou Xipu Materials Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. [1][3]. - The proposed penalties include a warning and a fine of 3 million yuan for the company, 1.5 million yuan for Wu Shaoqin, and 600,000 yuan for Li Lan, totaling 5.1 million yuan [1][3]. Group 2: Acquisition Details - The acquisition plan disclosed on September 22, 2025, indicated that the company intended to purchase 100% of Xipu Materials and 40% of Beid Pharmaceutical, which was expected to constitute a major asset restructuring [1][3]. - Xipu Materials, established in November 2020, focuses on high-end semiconductor materials and has achieved international advanced technology levels, with significant growth potential [4]. - Xipu Materials reported revenues of 38.54 million yuan in 2023 and 98.54 million yuan in 2024, with net profits of 40,800 yuan and 1.377 million yuan, respectively [5]. Group 3: Beid Pharmaceutical Overview - Beid Pharmaceutical, a subsidiary in which the company holds a 60% stake, was established in November 2004 and focuses on the research, manufacturing, and sales of various medications [7]. - The company reported revenues of 335.95 million yuan in 2023 and 330.37 million yuan in 2024, with net profits of 5.4 million yuan and 13.87 million yuan, respectively [10].